Transaction DateRecipientSharesTypePriceValue
31st December 2020David G Foster11,052Open or private sale$6.38$70,511.76
31st December 2020Anna Berkenblit2,203Grant/award etc.$4.04$8,900.12
31st December 2020David G Foster362Grant/award etc.$4.04$1,462.48
31st December 2020David G Foster27,240Exercise of derivative$0.00
31st December 2020Theresa Wingrove2,659Grant/award etc.$4.04$10,742.36
1st July 2020David G Foster342Grant/award etc.$3.91$1,337.22
30th June 2020Anna Berkenblit3,047Grant/award etc.$3.91$11,913.77
30th June 2020Mark J Enyedy5,241Grant/award etc.$3.91$20,492.31
30th June 2020Thomas Ryll5,241Grant/award etc.$3.91$20,492.31
30th June 2020Theresa Wingrove2,593Grant/award etc.$3.91$10,138.63
Immuno Gen
Immuno Gen logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

ImmunoGen, Inc. was founded in March 1981 and is headquartered in Waltham, MA. Its product candidates include Mirvetuximab soravtansine, Coltuximbe ravtansin, IMGN7779 and IMGN632.

Ticker: IMGN
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 855654
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $220 M (0%)
Assets, Current: $241 M (15%)
Property, Plant and Equipment, Net: $6 M (-15%)
Other Assets, Noncurrent: $8 M (100%)
Assets: $270 M (14%)
Accounts Payable, Current: $13 M (28%)
Liabilities, Current: $91 M (17%)
Other Liabilities, Noncurrent: $3 M (265%)
Liabilities: $294 M (-5%)
Common Stock, Value, Issued: $2 M (16%)
Common Stock, Shares, Issued: $175 Th (-99%)
Additional Paid in Capital, Common Stock: $1 B (8%)
Retained Earnings (Accumulated Deficit): $1 B (3%)
Stockholders' Equity (Parent): $25 M (0%)
Liabilities and Equity: $270 M (14%)
Research and Development: $23 M (-54%)
General and Administrative Expenses: $10 M (-47%)
Restructuring Charges: $699 Th (-54%)
Operating Income/Loss: $18 M (-56%)